Targeting the actin cytoskeleton: selective antitumor action via trapping PKCɛ

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Biology

Background:

• Targeting the actin cytoskeleton (CSK) is a promising cancer therapy strategy.
• Mechanisms of natural compounds targeting actin CSK and their tumor-specific actions remain unclear.
• Chondramide, a myxobacterial compound, interferes with actin CSK dynamics.

Purpose of the Study:

• To elucidate the cytotoxic mechanisms of actin targeting by Chondramide in breast cancer cells.
• To investigate the tumor-specific action of actin-binding agents.
• To identify the link between actin CSK and apoptosis induction.

Main Methods:

• Utilized fluorescence-based analysis (fluorescence recovery after photobleaching - FRAP) to assess actin filament dynamics.
• Analyzed apoptosis markers including phosphatidylserine exposure, cytochrome C release, and caspase activation.
• Investigated mitochondrial permeability transition (MPT) modulators (Hexokinase II, VDAC, Bad) and protein kinase C-epsilon (PKCɛ).

Main Results:

• Chondramide inhibited actin CSK dynamics and induced apoptosis in breast cancer cells (MCF7, MDA-MB-231).
• Chondramide promoted MPT by affecting Hexokinase II/VDAC interaction and Bad recruitment to mitochondria.
• Overexpressed PKCɛ, identified as a link between actin CSK and apoptosis, accumulated in Chondramide-induced actin bundles and lost activity.
• Non-tumorigenic MCF-10A cells showed resistance to Chondramide, correlating with low PKCɛ levels.
• Chondramide demonstrated in vivo efficacy in a xenograft breast cancer model by abrogating PKCɛ signaling.

Conclusions:

• Chondramide induces apoptosis in breast cancer cells by targeting the actin cytoskeleton and inhibiting PKCɛ.
• Trapping PKCɛ via Chondramide-induced actin hyperpolymerization confers tumor cell specificity.
• Actin-stabilizing agents targeting PKCɛ represent a potential new class of innovative cancer drugs.